These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29515002)

  • 1. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management.
    Sun X; Xiao Z; Chen G; Han Z; Liu Y; Zhang C; Sun Y; Song Y; Wang K; Fang F; Wang X; Lin Y; Xu L; Shao L; Li J; Cheng Z; Gambhir SS; Shen B
    Sci Transl Med; 2018 Mar; 10(431):. PubMed ID: 29515002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel anilino quinazoline-based EGFR tyrosine kinase inhibitors for treatment of non-small cell lung cancer.
    Yang L; Liu S; Chu J; Miao S; Wang K; Zhang Q; Wang Y; Xiao Y; Wu L; Liu Y; Yu L; Yu C; Liu X; Ke M; Cheng Z; Sun X
    Biomater Sci; 2021 Jan; 9(2):443-455. PubMed ID: 32236267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of 99mTc-HYNIC-MPG as a novel SPECT radiotracer to detect EGFR-activating mutations in NSCLC.
    Xiao Z; Song Y; Kai W; Sun X; Shen B
    Oncotarget; 2017 Jun; 8(25):40732-40740. PubMed ID: 28489575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of
    Lv Z; Fan J; Xu J; Wu F; Huang Q; Guo M; Liao T; Liu S; Lan X; Liao S; Geng W; Jin Y
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs.
    Yoshida T; Tanaka H; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Iwata H; Hida T; Yatabe Y
    Lung Cancer; 2016 Oct; 100():14-19. PubMed ID: 27597275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons.
    Xu D; Yu F; Guo T; Zhou Y; Zhang J; Li Y; Jiang S; Mao J; Yang X; Chu L; Chu X; Wang S; Ni J; Zhu Z
    Br J Radiol; 2022 Aug; 95(1136):20220035. PubMed ID: 35611637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD147-mediated glucose metabolic regulation contributes to the predictive role of
    Li X; Fu Q; Zhu Y; Wang J; Liu J; Yu X; Xu W
    Mol Carcinog; 2019 Feb; 58(2):247-257. PubMed ID: 30320488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic and predictive efficacy of
    Guo Y; Zhu H; Yao Z; Liu F; Yang D
    Eur J Radiol; 2021 Aug; 141():109792. PubMed ID: 34062472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.
    Shiri I; Maleki H; Hajianfar G; Abdollahi H; Ashrafinia S; Hatt M; Zaidi H; Oveisi M; Rahmim A
    Mol Imaging Biol; 2020 Aug; 22(4):1132-1148. PubMed ID: 32185618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-invasive decision support for NSCLC treatment using PET/CT radiomics.
    Mu W; Jiang L; Zhang J; Shi Y; Gray JE; Tunali I; Gao C; Sun Y; Tian J; Zhao X; Sun X; Gillies RJ; Schabath MB
    Nat Commun; 2020 Oct; 11(1):5228. PubMed ID: 33067442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiogenomic Models Using Machine Learning Techniques to Predict EGFR Mutations in Non-Small Cell Lung Cancer.
    Nair JKR; Saeed UA; McDougall CC; Sabri A; Kovacina B; Raidu BVS; Khokhar RA; Probst S; Hirsh V; Chankowsky J; Van Kempen LC; Taylor J
    Can Assoc Radiol J; 2021 Feb; 72(1):109-119. PubMed ID: 32063026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.
    Guan J; Xiao NJ; Chen M; Zhou WL; Zhang YW; Wang S; Dai YM; Li L; Zhang Y; Li QY; Li XZ; Yang M; Wu HB; Chen LH; Liu LY
    Medicine (Baltimore); 2016 Jul; 95(30):e4421. PubMed ID: 27472739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Epidermal Growth Factor Receptor Mutation on Positron Emission Tomography/Computed Tomography in Lung Cancer.
    Park JS; Park HY; Choi Y
    Anticancer Res; 2024 Jun; 44(6):2681-2687. PubMed ID: 38821597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of interim
    Shao D; Cheng Y; Yuan ZS; Jiang BY; Wang SX
    Lung Cancer; 2020 Nov; 149():137-143. PubMed ID: 33011375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis.
    Chen L; Zhou Y; Tang X; Yang C; Tian Y; Xie R; Chen T; Yang J; Jing M; Chen F; Wang C; Sun H; Huang Y
    Int J Oncol; 2019 Jan; 54(1):370-380. PubMed ID: 30431083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by
    Iommelli F; De Rosa V; Terlizzi C; Monti M; Panico M; Fonti R; Del Vecchio S
    Clin Cancer Res; 2018 Jul; 24(13):3126-3136. PubMed ID: 29618618
    [No Abstract]   [Full Text] [Related]  

  • 18. Can
    Du B; Wang S; Cui Y; Liu G; Li X; Li Y
    BMJ Open; 2021 Jun; 11(6):e044313. PubMed ID: 34103313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying advanced stage NSCLC patients who benefit from afatinib therapy using
    van de Stadt EA; Yaqub M; Lammertsma AA; Poot AJ; Schuit RC; Remmelzwaal S; Schwarte LA; Smit EF; Hendrikse H; Bahce I
    Lung Cancer; 2021 May; 155():156-162. PubMed ID: 33836373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current Status and Progress in Molecular Imaging of Non-small Cell Lung 
Cancer for Molecular Targeted EGFR-TKI Treatment Sensitivity and 
Treatment Tolerance Prediction].
    Dai D; Xu W; Wang Q; Li X; Zhu Y
    Zhongguo Fei Ai Za Zhi; 2017 Dec; 20(12):852-856. PubMed ID: 29277186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.